JP2003531173A - ゾルピデムヘミタートレイト - Google Patents

ゾルピデムヘミタートレイト

Info

Publication number
JP2003531173A
JP2003531173A JP2001577956A JP2001577956A JP2003531173A JP 2003531173 A JP2003531173 A JP 2003531173A JP 2001577956 A JP2001577956 A JP 2001577956A JP 2001577956 A JP2001577956 A JP 2001577956A JP 2003531173 A JP2003531173 A JP 2003531173A
Authority
JP
Japan
Prior art keywords
zolpidem hemitartrate
zolpidem
hemitartrate
particles
microns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001577956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003531173A5 (enExample
Inventor
アロンヒム，ジュディス
レオノブ，デイビッド
メサロス−ソス，エルゼベト
サイー，サボレス
サボ，チャバ
ザブロブ，シュロモ
Original Assignee
テバ ファーマシューティカル インダストリーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27394001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2003531173(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by テバ ファーマシューティカル インダストリーズ リミティド filed Critical テバ ファーマシューティカル インダストリーズ リミティド
Publication of JP2003531173A publication Critical patent/JP2003531173A/ja
Publication of JP2003531173A5 publication Critical patent/JP2003531173A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Liquid Machine Or Engine Such As Wave Power Use (AREA)
  • Suspension Of Electric Lines Or Cables (AREA)
  • Amplifiers (AREA)
  • Supply Devices, Intensifiers, Converters, And Telemotors (AREA)
JP2001577956A 2000-04-24 2001-04-24 ゾルピデムヘミタートレイト Withdrawn JP2003531173A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US19929800P 2000-04-24 2000-04-24
US60/199,298 2000-04-24
US20602500P 2000-05-22 2000-05-22
US60/206,025 2000-05-22
US22536400P 2000-08-14 2000-08-14
US60/225,364 2000-08-14
PCT/US2001/013175 WO2001080857A1 (en) 2000-04-24 2001-04-24 Zolpidem hemitartrate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006033099A Division JP2006137778A (ja) 2000-04-24 2006-02-09 ゾルピデムヘミタートレイト

Publications (2)

Publication Number Publication Date
JP2003531173A true JP2003531173A (ja) 2003-10-21
JP2003531173A5 JP2003531173A5 (enExample) 2005-12-22

Family

ID=27394001

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2001577956A Withdrawn JP2003531173A (ja) 2000-04-24 2001-04-24 ゾルピデムヘミタートレイト
JP2006033099A Pending JP2006137778A (ja) 2000-04-24 2006-02-09 ゾルピデムヘミタートレイト
JP2006177160A Pending JP2006249105A (ja) 2000-04-24 2006-06-27 ゾルピデムヘミタートレイト

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2006033099A Pending JP2006137778A (ja) 2000-04-24 2006-02-09 ゾルピデムヘミタートレイト
JP2006177160A Pending JP2006249105A (ja) 2000-04-24 2006-06-27 ゾルピデムヘミタートレイト

Country Status (21)

Country Link
US (8) US20020077332A1 (enExample)
EP (1) EP1292304B1 (enExample)
JP (3) JP2003531173A (enExample)
KR (1) KR20030069796A (enExample)
AT (4) ATE348613T1 (enExample)
AU (2) AU2001257213B2 (enExample)
CA (1) CA2406982A1 (enExample)
CZ (1) CZ20023775A3 (enExample)
DE (7) DE60122216T2 (enExample)
DK (1) DK1292304T3 (enExample)
ES (4) ES2239558T3 (enExample)
HR (1) HRP20020909A2 (enExample)
HU (1) HUP0300701A2 (enExample)
IL (1) IL152411A0 (enExample)
NZ (1) NZ522015A (enExample)
PL (1) PL358548A1 (enExample)
PT (3) PT1541146E (enExample)
SE (1) SE5292304T3 (enExample)
SK (1) SK16372002A3 (enExample)
WO (1) WO2001080857A1 (enExample)
YU (1) YU79402A (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510163A (ja) * 2005-10-03 2009-03-12 マリンクロッド・インコーポレイテッド ヘミ酒石酸および酒石酸ゾルピデム多形の製造方法
WO2011115069A1 (ja) * 2010-03-19 2011-09-22 第一三共株式会社 結晶の網羅的探索
JP2016510752A (ja) * 2013-03-06 2016-04-11 ヤンセン ファーマシューティカ エヌ．ベー． ヒスタミンｈ４受容体のベンゾイミダゾール−２−イルピリミジンモジュレータ

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001284322A1 (en) 2000-08-29 2002-03-13 Ranbaxy Laboratories Limited Synthesis of n,n-dimethyl-3-(4-methyl) benzoyl propionamide, a key intermediate of zolpidem
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
WO2004058758A1 (en) 2002-12-18 2004-07-15 Mallinckrodt Inc. Synthesis of heteroaryl acetamides
WO2004087703A1 (en) * 2003-03-12 2004-10-14 Sun Pharmaceutical Industries Limited Process for the preparation of n,n,6-trimethyl-2-(4-methylphenyl)-imidazo[1,2-a]pyridine-3-acetamide
EP1660496A1 (en) * 2003-07-31 2006-05-31 Ranbaxy Laboratories Limited Process for the synthesis of zolpidem
KR20070030178A (ko) * 2004-02-17 2007-03-15 트랜스오랄 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법
US20080262025A1 (en) * 2004-07-16 2008-10-23 Yatendra Kumar Processes for the Preparation of Zolpidem and its Hemitartrate
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
BRPI0609984A2 (pt) * 2005-05-25 2010-05-18 Transcept Pharmaceuticals Inc uso de zolpidem ou um sal do mesmo
EP1937265A2 (en) * 2005-08-19 2008-07-02 Aventis Pharmaceuticals Inc. Comination of a hypnotic agent and r(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenl)ethyl]-4-piperidinemethanol and therapeutic application thereof
MX2008001778A (es) * 2005-08-19 2008-04-07 Aventis Pharma Inc Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
CN101291654A (zh) * 2005-10-17 2008-10-22 马林克罗特公司 片剂基质中唑吡坦的多晶型转化
US20070098788A1 (en) * 2005-10-28 2007-05-03 Gore Subhash P Non-benzodiazepine hypnotic compositions
ATE478067T1 (de) 2006-03-31 2010-09-15 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors
WO2008067549A2 (en) * 2006-11-30 2008-06-05 Transcept Pharmaceuticals, Inc. Stabilized zolpidem pharmaceutical compositions
US20080145425A1 (en) * 2006-12-15 2008-06-19 Pliva Research & Development Limited Pharmaceutical composition of zolpidem
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
EA020090B1 (ru) * 2008-06-30 2014-08-29 Янссен Фармацевтика Нв Способ получения и рекристаллизации кристаллического гемитартрата бензоимидазол-2-илпиримидинового производного
MY192644A (en) 2009-11-27 2022-08-29 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
CN116283958B (zh) * 2021-12-03 2026-02-24 山东新时代药业有限公司 唑吡坦共晶体及其制备方法
CN116283957A (zh) * 2021-12-03 2023-06-23 山东新时代药业有限公司 唑吡坦水合物及其制备方法
CN117907368A (zh) * 2024-01-27 2024-04-19 鲁南贝特制药有限公司 一种酒石酸唑吡坦药用晶型d中晶型a、e的定量测定方法
CN118750459B (zh) * 2024-07-22 2025-04-01 常州市武进中医医院 一种酒石酸唑吡坦片及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
FR2408345A1 (fr) * 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
US4302446A (en) * 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
IT1130924B (it) * 1980-03-06 1986-06-18 Secifarma Spa Procedimento per la preparazione di spironolattone micronizzato
DE3018940A1 (de) * 1980-05-17 1981-11-26 Hoechst Ag, 6000 Frankfurt Verwendung eines vinylchlorid-pfropf-copolymerisates in der plastisolverarbeitung
FR2492382A1 (fr) * 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
FR2525601A1 (fr) * 1982-04-21 1983-10-28 Synthelabo Derives d'imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
US4675323A (en) * 1985-08-06 1987-06-23 Synthelabo Imidazo(1,2-a)quinoline derivatives useful as anxiolytic agents
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
FR2600650B1 (fr) * 1986-06-27 1988-09-09 Synthelabo Procede de preparation d'imidazopyridines et composes intermediaires
FR2606410B1 (fr) * 1986-11-07 1989-02-24 Synthelabo Imidazopyridines, leur preparation et leur application en therapeutique
DE3865073D1 (de) * 1987-03-27 1991-10-31 Synthelabo Imidazopyridinderivate, ihre herstellung und therapeutische verwendung.
US5271944A (en) * 1991-04-05 1993-12-21 Biofor, Ltd. Pharmacologically enhanced formulations
IT1276522B1 (it) * 1995-04-07 1997-10-31 Elena Benincasa Uso dello zolpidem per il trattamento terapeudico di sindromi neuropsichiatriche associate a disfunsione e di circuiti neurali dei
PT1163241E (pt) * 1999-03-25 2005-08-31 Synthon Bv Sais de zolpidem
DK1038875T3 (da) * 1999-03-25 2003-09-29 Synthon Bv Imidazopyridine- derivativer og fremgangsmåde til fremstilling deraf
WO2001042239A1 (en) * 1999-12-13 2001-06-14 Sumika Fine Chemicals Co., Ltd. Process for the preparation of a pyridinemethanol compound

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510163A (ja) * 2005-10-03 2009-03-12 マリンクロッド・インコーポレイテッド ヘミ酒石酸および酒石酸ゾルピデム多形の製造方法
WO2011115069A1 (ja) * 2010-03-19 2011-09-22 第一三共株式会社 結晶の網羅的探索
JP2016510752A (ja) * 2013-03-06 2016-04-11 ヤンセン ファーマシューティカ エヌ．ベー． ヒスタミンｈ４受容体のベンゾイミダゾール−２−イルピリミジンモジュレータ

Also Published As

Publication number Publication date
DE60122944D1 (de) 2006-10-19
PT1541146E (pt) 2007-01-31
AU5721301A (en) 2001-11-07
ATE335481T1 (de) 2006-09-15
ATE338550T1 (de) 2006-09-15
DE60125429D1 (de) 2007-02-01
EP1292304A4 (en) 2003-07-23
US20040214858A1 (en) 2004-10-28
DK1292304T3 (da) 2005-12-19
JP2006137778A (ja) 2006-06-01
DE20122435U1 (de) 2005-10-06
AU2001257213B2 (en) 2005-09-29
US20040220212A1 (en) 2004-11-04
CZ20023775A3 (cs) 2003-10-15
ES2239558T1 (es) 2005-10-01
US20020077332A1 (en) 2002-06-20
DE04010651T1 (de) 2005-09-01
ES2238941T1 (es) 2005-09-16
DE60122216D1 (de) 2006-09-21
ES2239558T3 (es) 2007-04-01
ATE348613T1 (de) 2007-01-15
ES2238941T3 (es) 2007-04-01
HRP20020909A2 (en) 2004-08-31
US20040214859A1 (en) 2004-10-28
SK16372002A3 (sk) 2003-04-01
NZ522015A (en) 2004-08-27
DE04010435T1 (de) 2005-09-01
DE60122944T2 (de) 2007-04-12
EP1292304A1 (en) 2003-03-19
SE5292304T3 (enExample) 2005-11-02
PL358548A1 (en) 2004-08-09
PT1475093E (pt) 2006-11-30
US20040220210A1 (en) 2004-11-04
JP2006249105A (ja) 2006-09-21
ES2248321T3 (es) 2006-03-16
IL152411A0 (en) 2003-05-29
WO2001080857A9 (en) 2002-06-27
US20040220213A1 (en) 2004-11-04
US20070037843A1 (en) 2007-02-15
ATE308324T1 (de) 2005-11-15
CA2406982A1 (en) 2001-11-01
PT1473036E (pt) 2006-10-31
US20040220211A1 (en) 2004-11-04
DE60114617T2 (de) 2006-07-27
DE60114617D1 (de) 2005-12-08
DE60125429T2 (de) 2007-09-27
EP1292304B1 (en) 2005-11-02
ES2277301T3 (es) 2007-07-01
KR20030069796A (ko) 2003-08-27
DE60122216T2 (de) 2007-08-30
YU79402A (sh) 2006-03-03
HUP0300701A2 (hu) 2003-07-28
WO2001080857A1 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
EP1292304B1 (en) Zolpidem hemitartrate
CN105209437B (zh) 心肌肌球蛋白激动剂的盐和制备盐的方法
AU2001257213A1 (en) Zolpidem hemitartrate
JP2021523918A (ja) Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態
TW202335670A (zh) ｛［５—（３—氯苯基）—３—羥基吡啶—２—羰基］胺基｝乙酸之固體型式，其組合物及用途
JP2009524685A (ja) ９−ヒドロキシ−リスペリドン（パリペリドン）の結晶型
JP2007514000A (ja) テガセロッド塩基及びその塩の多形現象形
HRP20100281A2 (hr) Kristalni oblici palonosetron hidroklorida
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
MX2007016179A (es) Formas cristalinas de o-desmetilvenlafaxina.
TWI705065B (zh) 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途
EP1473036B1 (en) Zolpidem hemitartrate solvate
ZA200208454B (en) Zolpidem hemitartrate.
HK1219484B (en) Salt of omecamtiv mecarbil and process for preparing salt

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040823

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20050622

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20050719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20051108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20051118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20060912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070222

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20070327

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20070727

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090907